Table 3.

Association between CKD–mineral and bone disorder phenotypes and outcomes within baseline risk groups defined by the distribution of the 16-month predicted outcome

End Point and Sample Size	Exposure Group			Hazard Ratio (95% Confidence Interval)
	Parathyroid Hormone	Calcium	Phosphate	Quartile 1 (n=5929)	Quartiles 2–3 (n=11,858)	Quartile 4 (n=5929)	Overall (n=23,716)
Death
514	High	High	High		1.72 (1.31 to 2.25)		1.35 (1.12 to 1.62)
2803	High	Normal	High		1.58 (1.36 to 1.84)		1.15 (1.04 to 1.28)
861	High	Normal	Target
593	Target high	High	High		1.43 (1.08 to 1.88)	1.24 (1.00 to 1.55)	1.20 (1.02 to 1.42)
631	Target high	High	Target			1.39 (1.15 to 1.69)	1.29 (1.10 to 1.50)
4117	Target high	Normal	High
3828	Target high	Normal	Target		1.31 (1.14 to 1.50)
665	Target low	High	Target
2624	Target low	Normal	High
5224	Target low	Normal	Target	Reference category for all models
574	Low	Normal	High		1.44 (1.09 to 1.91)
1282	Low	Normal	Target
Cardiovascular hospitalization or death
514	High	High	High		1.35 (1.11 to 1.64)	1.40 (1.12 to 1.74)	1.33 (1.16 to 1.52)
2803	High	Normal	High	1.33 (1.10 to 1.61)	1.27 (1.15 to 1.41)	1.33 (1.18 to 1.49)	1.28 (1.20 to 1.38)
861	High	Normal	Target
593	Target high	High	High	1.87 (1.37 to 2.54)	1.34 (1.11 to 1.61)	1.32 (1.10 to 1.59)	1.37 (1.22 to 1.55)
631	Target high	High	Target	1.55 (1.07 to 2.25)		1.26 (1.06 to 1.50)	1.23 (1.09 to 1.38)
4117	Target high	Normal	High		1.26 (1.16 to 1.38)	1.19 (1.07 to 1.32)	1.20 (1.13 to 1.28)
3828	Target high	Normal	Target			1.11 (1.01 to 1.23)	1.08 (1.01 to 1.15)
665	Target low	High	Target
2624	Target low	Normal	High
5224	Target low	Normal	Target	Reference category for all models
574	Low	Normal	High		1.22 (1.00 to 1.47)		1.19 (1.05 to 1.36)
1282	Low	Normal	Target

Only statistically significant (P<0.05) results are shown to facilitate readability.